Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs
Prnewswire·2025-10-24 20:55

Core Insights - Elanco Animal Health has received Emergency Use Authorization (EUA) from the FDA for Credelio (lotilaner) to treat New World screwworm (NWS) infestations in dogs, marking the first EUA granted for this purpose in dogs [1][10] - The authorization is a proactive measure in response to confirmed NWS cases detected near the U.S.-Mexico border, allowing veterinarians and pet owners to have a treatment option ready [1][10] Summary by Sections Emergency Use Authorization - The EUA for Credelio is based on a study showing 100% efficacy against NWS larvae within 24 hours of treatment in naturally infested dogs [2] - The study was conducted on a limited population of eleven dogs in Brazil, raising questions about its applicability to the U.S. population [3] Treatment and Prevention - Effective parasite protection is crucial, as NWS infestations begin when female flies lay eggs on open wounds, with one female capable of laying 200-300 eggs at a time [4] - The U.S. Animal Plant Health and Inspection Service (APHIS) recommends protecting pets from wound-causing parasites to prevent NWS infestations [5] Veterinary Insights - Veterinarians emphasize the importance of preventing or rapidly treating wounds to protect pets from NWS, suggesting year-round flea and tick protection as a preventive measure [6] Company Background - Elanco Animal Health is a global leader in animal health, dedicated to innovating products and services for disease prevention and treatment in animals, with a commitment to improving animal health and community impact [9]